Search
X-376
go.drugbank.com/drugs/DB13104InvestigationalX-376 is an inhibitor of the anaplastic lymphoma kinase (ALK) which can penetrate the blood brain barrier.[A265085]
Trapidil
go.drugbank.com/drugs/DB09283ExperimentalTrapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease.
Bimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigationalBimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment
Nerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigational[L54126] Compared to pan-PDE4 inhibitors, selective PDE4B inhibitors are associated with a lower potential for gastrointestinal adverse events.[A274581] On December 19, 2025, the U.S.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsTromethamine
go.drugbank.com/drugs/DB03754ApprovedInvestigationalas an alkalizer. … An organic amine proton acceptor.
Tribromsalan
go.drugbank.com/drugs/DB20138ApprovedWithdrawnTribromsalan has a monoisotopic molecular weight of 446.81 Da.
N-methylnicotinamide
go.drugbank.com/drugs/DB08840InvestigationalN-methylnicotinamide is an experimental drug with no approved indication or marketed formulation.
Imipenem
go.drugbank.com/drugs/DB01598ApprovedInvestigationalSimilar compounds include [meropenem], known for having greater activity against Gram negative bacteria, and the newer [ertapenem] which exhibits a longer half-life due to increased binding to plasma proteins
Degarelix
go.drugbank.com/drugs/DB06699ApprovedInvestigationalChemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.